GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT01301092

CompletedPhase 1Results posted

A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.

A Study to Evaluate the Safety, Tolerability, and Absolute Bioavailability of Subcutaneous LY2189265

Lead sponsor

Eli Lilly and Company

Asset

Dulaglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 23-35•Healthy volunteers

Primary endpoints

•Dose Normalized AUC of LY2189265•Cmax of LY2189265

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01301092

Org study ID13989

Secondary IDH9X-MC-GBDREli Lilly and Company

Timeline

Milestones

Study first posted2011-02-23estimated

Last update posted2014-10-07estimated

Results first posted2014-10-07estimated

Study start2011-02 (month precision)

Primary completion2011-08actual (month precision)

Study completion2011-08actual (month precision)

Assets

Investigational agents

Dulaglutide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Are overtly healthy males or females, as determined by medical history and physical examination.

•Male subjects with female partners of child-bearing potential, or partners who are pregnant or breastfeeding, agree to use a reliable method of contraception from the time of the first dose until 3 months after the last dose of investigational product, as determined by the investigator. The method may be one of the following: condom with spermicidal agent, male subject sterilization, true abstinence (which is in line with the subject's usual lifestyle choice; withdrawal or calendar methods are not considered acceptable).

•Female subjects not of child-bearing potential (that is, are postmenopausal or permanently sterilized [for example, tubal occlusion, hysterectomy, bilateral salpingectomy]). Such subjects will not be required to use contraception but must test negative for pregnancy at the time of enrollment. Postmenopausal is defined as at least 1 year post cessation of menses (without an alternative medical cause) with follicle stimulating hormone (FSH) greater than or equal to 40 milli-international units per milliliter (mIU/mL).

•Female subjects who have undergone sterilization by tubal ligation: agree to use a condom in conjunction with spermicidal gel, foam, cream, film or suppository from the time of screening until 3 months after the last dose of investigational product. Such subjects must also test negative for pregnancy at the time of enrollment.

•Have a body mass index (BMI) of between 23.0 and 35.0 kilogram/square meter (kg/m²), inclusive.

•Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not clinically significant by the investigator.

•Have normal sitting blood pressure and pulse rate as determined by the investigator, or with changes compatible with their age.

•Have venous access sufficient to allow for blood sampling and/or IV administration of investigational product as per the protocol.

•Are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures.

•Have given written informed consent approved by Lilly and the ethical review board (ERB) governing the site.

Exclusion criteria

•Are currently enrolled in, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device, or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

•Are women of child bearing potential

•Have known allergies to Glucagon-like peptide-1 (GLP-1)-related compounds including LY2189265.

•Are persons who have previously completed or withdrawn from this study or any other study investigating LY2189265.

•Have an abnormality in the 12-lead Electrocardiogram (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study.

•Have a history or presence of gastrointestinal disorder (including pancreatitis [history of chronic pancreatitis or idiopathic acute pancreatitis] or gall bladder disease), or gastrointestinal disease that impacts gastric emptying (GE) (for example, gastric bypass surgery, pyloric stenosis) or could be aggravated by GLP analogs (for example, esophageal reflux). Subjects having had cholecystolithiasis (removal of gall stones), cholecystectomy (removal of gall bladder) and/or appendectomy in the past with no further sequelae may be included in the study at the discretion of the screening physician.

•Have a history or presence of significant active neuropsychiatric disease

•Regularly use known drugs of abuse and/or show positive findings on urinary drug screening.

•Show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies.

•Show evidence of hepatitis C and/or positive hepatitis C antibody.

•Show evidence of hepatitis B and/or positive hepatitis B surface antigen.

•Are women with a positive pregnancy test or women who are lactating.

•Use or intend to use over-the-counter medication other than paracetamol within 7 days prior to dosing or prescription medication (with the exception of vitamin/mineral supplements and/or hormone replacement therapy and/or thyroid replacement therapy) within 14 days prior to dosing.

•Have donated blood of more than 500 mL within the last month.

•Are subjects who have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females), (1 unit = 12 ounce [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits), or are unwilling to stop alcohol consumption from at least 24 hours prior to screening and each dose, and while resident at the clinical research unit (CRU).

•Are subjects who smoke more than 10 cigarettes per day, are unwilling to refrain from smoking on the day of LY2189265 administration and while resident.

•Are subjects who, in the opinion of the investigator, are in any way unsuitable to participate in the study.

Endpoints (8)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

8 endpoints

Primary/registry result

Dose Normalized Area Under the Concentration Time Curve (AUC) of LY2189265: Subcutaneous (SC) to Intravenous (IV)

Time frame:Predose up to 336 hours postdose

AUC₀–∞

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanograms*hour/milliliter/milligram	95% CI
Part B: LY2189265 Subcutaneous	10256	8964 – 11734
Part B: LY2189265 Intravenous	23150	20234 – 26485

Ratio of Geometric LS Mean0.44390% CI0.395 – 0.497Mixed Linear effects model analyses

Primary/registry result

Maximum Concentration (Cmax) of LY2189265: Subcutaneous (SC) to Intravenous (IV)

Time frame:Predose up to 336 hours postdose

Cmax

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanograms/milliliter (ng/mL)	95% CI
Part B: LY2189265 Subcutaneous	80.7	71.8 – 90.8
Part B: LY2189265 Intravenous	38.3	34.1 – 43.1

Ratio of Geometric LS Mean2.1090% CI1.84 – 2.41Mixed Linear effects model analyses

Primary/protocol endpoint

Dose Normalized Area Under the Concentration Time Curve (AUC) of LY2189265: Subcutaneous (SC) to Intravenous (IV)

Time frame:Predose up to 336 hours postdose

AUC₀–∞

concentration, descriptive

Primary/protocol endpoint

Maximum Concentration (Cmax) of LY2189265: Subcutaneous (SC) to Intravenous (IV)

Time frame:Predose up to 336 hours postdose

Cmax

concentration, descriptive

Secondary/registry result

Area Under the Concentration Time Curve (AUC) of LY2189265: Intramuscular (IM) to Subcutaneous (SC)

Time frame:Predose up to 336 hours postdose

AUC₀–∞

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanogramshour/milliliter (ngh/mL)	95% CI
Part C: LY2189265 Intramuscular	9828	7525 – 12837
Part C: LY2189265 Subcutaneous	10215	7832 – 13323

Ratio of Geometric LS Means0.96290% CI0.858 – 1.08Mixed Linear effects model analyses

Secondary/registry result

)Maximum Concentration (Cmax) of LY2189265: Intramuscular (IM) to Subcutaneous (SC)

Time frame:Predose up to 336 hours postdose

Cmax

concentration, descriptive

Posted result

Group	Value (geometric_mean), nanograms/milliliter (ng/mL)	95% CI
Part C: LY2189265 Intramuscular	56.9	48.4 – 67.0
Part C: LY2189265 Subcutaneous	54.2	46.3 – 63.5

Ratio of Geometric LS Means1.0590% CI0.924 – 1.19Mixed Linear effects model analyses

Secondary/protocol endpoint

Area Under the Concentration Time Curve (AUC) of LY2189265: Intramuscular (IM) to Subcutaneous (SC)

Time frame:Predose up to 336 hours postdose

AUC₀–∞

concentration, descriptive

Secondary/protocol endpoint

)Maximum Concentration (Cmax) of LY2189265: Intramuscular (IM) to Subcutaneous (SC)

Time frame:Predose up to 336 hours postdose

Cmax

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableClinicalTrials.gov results section

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.